Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Charles Bennett and LeAnn Norris.
Connection Strength

2.901
  1. Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre-ibrutinib era: Incidence and risk factors. Cancer Med. 2019 05; 8(5):2233-2240.
    View in: PubMed
    Score: 0.177
  2. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. Oncologist. 2019 04; 24(4):537-548.
    View in: PubMed
    Score: 0.175
  3. Investigating Serious Adverse Drug Reactions in Patients Receiving Erythropoiesis-Stimulating Agents: A Root Cause Analysis Using the "ANTICIPATE" Framework. Am J Ther. 2018 Nov/Dec; 25(6):e670-e674.
    View in: PubMed
    Score: 0.171
  4. Reply to A.M. Zeidan et al. J Clin Oncol. 2017 10 01; 35(28):3265.
    View in: PubMed
    Score: 0.157
  5. Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR). Cancer Med. 2017 Jul; 6(7):1541-1551.
    View in: PubMed
    Score: 0.156
  6. Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia. J Oncol Pract. 2017 06; 13(6):e562-e573.
    View in: PubMed
    Score: 0.155
  7. Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome. J Clin Oncol. 2017 Jun 10; 35(17):1945-1951.
    View in: PubMed
    Score: 0.154
  8. Generic oncology drugs: are they all safe? Lancet Oncol. 2016 Nov; 17(11):e493-e501.
    View in: PubMed
    Score: 0.149
  9. Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia. Br J Haematol. 2018 01; 180(2):301-304.
    View in: PubMed
    Score: 0.148
  10. Toxicity and costs of toxicity associated with new cancer drugs: international implications. J Clin Oncol. 2014 Nov 10; 32(32):3591-2.
    View in: PubMed
    Score: 0.129
  11. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer. 2014 Aug 15; 120(16):2464-71.
    View in: PubMed
    Score: 0.125
  12. Emerging drugs for treatment of anemia of chronic kidney disease. Expert Opin Emerg Drugs. 2013 Dec; 18(4):421-9.
    View in: PubMed
    Score: 0.120
  13. Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis. J Natl Cancer Inst. 2013 Aug 07; 105(15):1072-3.
    View in: PubMed
    Score: 0.119
  14. Colony-stimulating factors for febrile neutropenia. N Engl J Med. 2013 07 18; 369(3):286.
    View in: PubMed
    Score: 0.119
  15. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med. 2013 Mar 21; 368(12):1131-9.
    View in: PubMed
    Score: 0.116
  16. A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012 Nov; 38(8):783-96.
    View in: PubMed
    Score: 0.113
  17. A tale of two citizens: a State Attorney General and a hematologist facilitate translation of research into US Food and Drug Administration actions--a SONAR report. J Oncol Pract. 2012 Nov; 8(6):e158-67.
    View in: PubMed
    Score: 0.111
  18. Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR). J Gen Intern Med. 2012 Dec; 27(12):1697-703.
    View in: PubMed
    Score: 0.110
  19. Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease. Clin Kidney J. 2012 Feb; 5(1):82-88.
    View in: PubMed
    Score: 0.107
  20. Caveat oncologist: clinical findings and consequences of distributing counterfeit erythropoietin in the United States. J Oncol Pract. 2012 Mar; 8(2):84-90.
    View in: PubMed
    Score: 0.106
  21. Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication. Expert Opin Drug Saf. 2011 Jul; 10(4):521-8.
    View in: PubMed
    Score: 0.102
  22. Hepatitis B Virus Reactivation: Risk Factors and Current Management Strategies. Pharmacotherapy. 2019 12; 39(12):1190-1203.
    View in: PubMed
    Score: 0.046
  23. Fluoroquinolone-related neuropsychiatric and mitochondrial toxicity: a collaborative investigation by scientists and members of a social network. J Community Support Oncol. 2016 Feb; 14(2):54-65.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.